Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - clopidogrelum, acidum acetylsalicylicum - filmtabletten - clopidogrelum 75 mg ut clopidogreli hydrogenosulfas 97.875 mg, acidum acetylsalicylicum 100 mg, maydis amylum, mannitolum, macrogolum 6000, cellulosum microcristallinum, hydroxypropylcellulosum, ricini oleum hydrogenatum, acidum stearicum, silica colloidalis anhydrica, pellicule: lactosum monohydricum 8 mg, hypromellosum, triacetinum, cera carnauba, e 171, e 172 (rubrum), pro compresso obducto. - inhibitor der aggregation thrombocytaire - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - acidum acetylsalicylicum, acidum ascorbicum - brausetabletten - acidum acetylsalicylicum 500 mg, acidum ascorbicum 250 mg, acidum citricum, natrii hydrogenocarbonas, natrii carbonas, natrii dihydrogenocitras anhydricus, natrii citras anhydricus, povidonum k 30, mannitolum, natrii docusas, simeticonum, natrii cyclamas, saccharinum natricum, aromatica (zitrone) cum sorbitolum, pro compresso corresp. natrium 381.04 mg. - linderung von fieber und schmerzen bei erkältungskrankheiten - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

amavita health care ag - acidum acetylsalicylicum - tabletten - acidum acetylsalicylicum 500 mg, excipiens pro compresso. - analgetikum, antipyretikum - synthetika human

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hänseler ag - acidum acetylsalicylicum, coffeinum - tabletten - säure acetylsalicylicum 500 mg, coffein 50 mg, saccharinum, excipiens pro compresso. - analgetikum, antipyretikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - acidum acetylsalicylicum - filmtabletten - acidum acetylsalicylicum 100 mg, cellulosum microcristallinum, maydis amylum, silica colloidalis anhydrica, acidum stearicum, Überzug: acidi methacrylici et ethylis acrylatis polymerisatum 1:1, polysorbatum 80, natrii laurilsulfas corresp. natrium 2 µg, triethylis citras, talcum pro compresso obducto. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, unsicheren angina pectoris - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hänseler ag - acidum acetylsalicylicum - tabletten - carbasalatum calcicum 528 mg endwerte. säure acetylsalicylicum 415 mg, excipiens pro compresso. - analgetikum, antipyretikum - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel-hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotische mittel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Europäische Union - Deutsch - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel (as hydrochloride) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotische mittel - clopidogrel ist indiziert bei erwachsenen zur prävention von atherothrombotischen ereignisse bei:patienten mit herzinfarkt (wenige tage bis weniger als 35 tage), mit ischämischen schlaganfall (7 tage bis weniger als 6 monate) oder etablierte periphere arterielle krankheit. patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation acute myocardial infarction, in kombination mit ass bei medizinisch behandelten patienten, für die eine thrombolytische therapie. weitere informationen finden sie in abschnitt 5.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bayer vital gmbh (8011204) - acetylsalicylsäure (ph.eur.); pseudoephedrinhydrochlorid - granulat zur herstellung einer suspension zum einnehmen - teil 1 - granulat zur herstellung einer suspension zum einnehmen; acetylsalicylsäure (ph.eur.) (00002) 500 milligramm; pseudoephedrinhydrochlorid (09585) 30 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bayer vital gmbh (8011204) - acetylsalicylsäure (ph.eur.); pseudoephedrinhydrochlorid - granulat zur herstellung einer suspension zum einnehmen - teil 1 - granulat zur herstellung einer suspension zum einnehmen; acetylsalicylsäure (ph.eur.) (00002) 500 milligramm; pseudoephedrinhydrochlorid (09585) 30 milligramm